Key points are not available for this paper at this time.
2639 Background: LB1410 is a recombinant humanized anti-PD-1/TIM-3 bispecific antibody (BsAb) developed by L updated data will be presented. Conclusions: LB1410 has manageable safety and shows preliminary efficacy. Additional dose and efficacy expansion study is ongoing in immunotherapy-naive pts with MSS CRC and pts who are resistant to immunotherapy. Clinical trial information: NCT05357651 .
Building similarity graph...
Analyzing shared references across papers
Loading...
Liu et al. (Sat,) studied this question.
www.synapsesocial.com/papers/68e66dc6b6db6435875f8b03 — DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.2639
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Jiajian Liu
Caicun Zhou
Wei Li
Journal of Clinical Oncology
Tongji University
Shanghai Pulmonary Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...